Company Description
Firefly Neuroscience, Inc., an artificial intelligence company, develops, markets, and distributes medical devices and technologies that allow high-resolution visualization and evaluation of the complex neurophysiological interconnections of the human brain in North America.
The company offers the Evoke System, a system used to perform electroencephalographic (EEG) and event-related potential (ERP) assessments, which are analyzed by its cloud-based platform and returned as structured reports designed to support clinical decision-making for various diseases, including depression, anxiety, ADHD, PTSD, MCI, dementia, Parkinson's disease, bipolar disorder, schizophrenia, schizoaffective disorder, ASD, and traumatic brain injury.
It serves clinicians. Firefly Neuroscience, Inc. was founded in 2006 and is based in Kenmore, New York.
| Country | United States |
| Founded | 2006 |
| Industry | Software - Application |
| Sector | Technology |
| Employees | 13 |
| CEO | Greg Lipschitz |
Contact Details
Address: 1100 Military Road Kenmore, New York 14217 United States | |
| Phone | 888 237 6412 |
| Website | fireflyneuro.com |
Stock Details
| Ticker Symbol | AIFF |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000803578 |
| CUSIP Number | 317970101 |
| ISIN Number | US3179701012 |
| Employer ID | 54-1167364 |
| SIC Code | 7372 |
Key Executives
| Name | Position |
|---|---|
| Greg Lipschitz | Chief Executive Officer and Director |
| David DeCaprio | President, Chief Operating Officer and Director |
| Paul Krzywicki CPA, CGA | Chief Financial Officer and Company Secretary |
| Gil Issachar | Chief Technology Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 13, 2026 | 10-Q | Quarterly Report |
| May 12, 2026 | 8-K | Current Report |
| Apr 22, 2026 | 8-K | Current Report |
| Apr 16, 2026 | D | Notice of Exempt Offering of Securities |
| Mar 31, 2026 | 10-K | Annual Report |
| Mar 12, 2026 | 8-K | Current Report |
| Feb 4, 2026 | 8-K | Current Report |
| Feb 3, 2026 | 424B5 | Filing |
| Jan 30, 2026 | SCHEDULE 13D/A | Filing |
| Dec 31, 2025 | SCHEDULE 13D/A | Filing |